A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study
-
Add time:07/25/2019 Source:sciencedirect.com
Objective.A phase II study was conducted to determine the efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments.
We also recommend Trading Suppliers and Manufacturers of FLAVOPIRIDOL HYDROCHLORIDE (cas 131740-09-5). Pls Click Website Link as below: cas 131740-09-5 suppliers
Prev:Flavopiridol inhibits interferon-γ-induced nitric oxide production in mouse vascular endothelial cells
Next:Improved survival with Simendan (cas 131741-08-7) after experimental myocardial infarction in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Flavopiridol inhibits interferon-γ-induced nitric oxide production in mouse vascular endothelial cells07/24/2019
- Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment07/23/2019
- Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: Comparison of chrysin and flavopiridol07/22/2019
-
Health and Chemical more >